Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01959685 · ClinicalTrials.gov registry record · Phase 1
A Dose Escalating Study to Determine the Tolerability and PK of a Single Dose of Androxal
A Phase 1 study, sponsored by Repros Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT01959685 is a Phase 1 study that has completed, run by Repros Therapeutics. The registered enrollment target is 9 participants.
The verdict
NCT01959685, a Phase 1 study, has completed, sponsored by Repros Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
To determine the tolerability and pharmacokinetics (PK) of a single dose of Androxal in healthy adult male subjects as the dose to be investigated in a thorough QT interval/corrected QT interval (QT/QTc) study.
Interventions
- DRUG Placebo
- DRUG Androxal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2013-10 |
| Est. Completion | 2013-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01959685
The ClinicalTrials.gov registry entry for NCT01959685 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Repros Therapeutics, which has 50 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01959685 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01959685 about?
NCT01959685 is a clinical study titled "A Dose Escalating Study to Determine the Tolerability and PK of a Single Dose of Androxal". To determine the tolerability and pharmacokinetics (PK) of a single dose of Androxal in healthy adult male subjects as the dose to be investigated in a thorough QT interval/corrected QT interval (QT/QTc) study.
What is the current status of trial NCT01959685?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2013-10. Estimated completion is 2013-11.
What interventions are being tested in trial NCT01959685?
The interventions under investigation include: Placebo (DRUG), Androxal (DRUG).
Who is sponsoring clinical trial NCT01959685?
This trial is sponsored by Repros Therapeutics, which has 50 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.